TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2015 DA - 2015// TI - Cancer statistics, 2015 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21254 DO - 10.3322/caac.21254 ID - Siegel2015 ER - TY - JOUR AU - Sweeney, C. J. AU - Chen, Y. H. AU - Carducci, M. AU - Liu, G. AU - Jarrard, D. F. AU - Eisenberger, M. AU - Wong, Y. N. AU - Hahn, N. AU - Kohli, M. AU - Cooney, M. M. PY - 2015 DA - 2015// TI - Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1503747 DO - 10.1056/NEJMoa1503747 ID - Sweeney2015 ER - TY - JOUR AU - Vale, C. L. AU - Burdett, S. AU - Rydzewska, L. H. AU - Albiges, L. AU - Clarke, N. W. AU - Fisher, D. AU - Fizazi, K. AU - Gravis, G. AU - James, N. D. AU - Mason, M. D. PY - 2016 DA - 2016// TI - Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data JO - The Lancet Oncology VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00489-1 DO - 10.1016/S1470-2045(15)00489-1 ID - Vale2016 ER - TY - JOUR AU - Kenmotsu, H. AU - Tanigawara, Y. PY - 2015 DA - 2015// TI - Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the western dose JO - Cancer Sci VL - 106 UR - https://doi.org/10.1111/cas.12647 DO - 10.1111/cas.12647 ID - Kenmotsu2015 ER - TY - JOUR AU - Lee, J. L. AU - Kim, J. E. AU - Ahn, J. H. AU - Lee, D. H. AU - Lee, J. AU - Kim, C. S. AU - Hong, J. H. AU - Hong, B. AU - Song, C. AU - Ahn, H. PY - 2010 DA - 2010// TI - Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea JO - Cancer Res Treat : official journal of Korean Cancer Association VL - 42 UR - https://doi.org/10.4143/crt.2010.42.1.12 DO - 10.4143/crt.2010.42.1.12 ID - Lee2010 ER - TY - JOUR AU - Grivas, P. D. AU - Robins, D. M. AU - Hussain, M. PY - 2013 DA - 2013// TI - Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer JO - Crit Rev Oncol Hematol VL - 85 UR - https://doi.org/10.1016/j.critrevonc.2012.05.003 DO - 10.1016/j.critrevonc.2012.05.003 ID - Grivas2013 ER - TY - STD TI - Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003;169:164–9. ID - ref7 ER - TY - JOUR AU - Park, Y. H. AU - Hwang, I. S. AU - Jeong, C. W. AU - Kim, H. H. AU - Lee, S. E. AU - Kwak, C. PY - 2009 DA - 2009// TI - Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer JO - J Urol VL - 181 UR - https://doi.org/10.1016/j.juro.2009.01.104 DO - 10.1016/j.juro.2009.01.104 ID - Park2009 ER - TY - JOUR AU - Mikah, P. AU - Krabbe, L. M. AU - Eminaga, O. AU - Herrmann, E. AU - Papavassilis, P. AU - Hinkelammert, R. AU - Semjonow, A. AU - Schrader, A. J. AU - Boegemann, M. PY - 2016 DA - 2016// TI - Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2260-y DO - 10.1186/s12885-016-2260-y ID - Mikah2016 ER - TY - JOUR AU - Scher, H. I. AU - Halabi, S. AU - Tannock, I. AU - Morris, M. AU - Sternberg, C. N. AU - Carducci, M. A. AU - Eisenberger, M. A. AU - Higano, C. AU - Bubley, G. J. AU - Dreicer, R. PY - 2008 DA - 2008// TI - Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.4487 DO - 10.1200/JCO.2007.12.4487 ID - Scher2008 ER - TY - JOUR AU - Soloway, M. S. AU - Hardeman, S. W. AU - Hickey, D. AU - Raymond, J. AU - Todd, B. AU - Soloway, S. AU - Moinuddin, M. PY - 1988 DA - 1988// TI - Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan JO - Cancer VL - 61 UR - https://doi.org/3.0.CO;2-Y DO - 3.0.CO;2-Y ID - Soloway1988 ER - TY - JOUR AU - Choueiri, T. K. AU - Xie, W. AU - D'Amico, A. V. AU - Ross, R. W. AU - Hu, J. C. AU - Pomerantz, M. AU - Regan, M. M. AU - Taplin, M. E. AU - Kantoff, P. W. AU - Sartor, O. AU - Oh, W. K. PY - 2009 DA - 2009// TI - Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24064 DO - 10.1002/cncr.24064 ID - Choueiri2009 ER - TY - JOUR AU - Huang, S. P. AU - Bao, B. Y. AU - Wu, M. T. AU - Choueiri, T. K. AU - Goggins, W. B. AU - Huang, C. Y. AU - Pu, Y. S. AU - Yu, C. C. AU - Huang, C. H. PY - 2011 DA - 2011// TI - Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy JO - Prostate VL - 71 UR - https://doi.org/10.1002/pros.21334 DO - 10.1002/pros.21334 ID - Huang2011 ER - TY - JOUR AU - Ji, G. AU - Song, G. AU - Huang, C. AU - He, S. AU - Zhou, L. PY - 2017 DA - 2017// TI - Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: a retrospective study JO - Medicine VL - 96 UR - https://doi.org/10.1097/MD.0000000000007823 DO - 10.1097/MD.0000000000007823 ID - Ji2017 ER - TY - JOUR AU - Halabi, S. AU - Armstrong, A. J. AU - Sartor, O. AU - de Bono, J. AU - Kaplan, E. AU - Lin, C. Y. AU - Solomon, N. C. AU - Small, E. J. PY - 2013 DA - 2013// TI - Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2013.50.3201 DO - 10.1200/JCO.2013.50.3201 ID - Halabi2013 ER - TY - JOUR AU - Hussain, M. AU - Tangen, C. M. AU - Higano, C. AU - Schelhammer, P. F. AU - Faulkner, J. AU - Crawford, E. D. AU - Wilding, G. AU - Akdas, A. AU - Small, E. J. AU - Donnelly, B. PY - 2006 DA - 2006// TI - Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162) JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.4246 DO - 10.1200/JCO.2006.06.4246 ID - Hussain2006 ER - TY - JOUR AU - Arai, Y. AU - Yoshiki, T. AU - Yoshida, O. PY - 1990 DA - 1990// TI - Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer JO - J Urol VL - 144 UR - https://doi.org/10.1016/S0022-5347(17)39757-4 DO - 10.1016/S0022-5347(17)39757-4 ID - Arai1990 ER - TY - JOUR AU - Gravis, G. AU - Boher, J. M. AU - Fizazi, K. AU - Joly, F. AU - Priou, F. AU - Marino, P. AU - Latorzeff, I. AU - Delva, R. AU - Krakowski, I. AU - Laguerre, B. PY - 2015 DA - 2015// TI - Prognostic factors for survival in noncastrate metastatic prostate Cancer: validation of the glass model and development of a novel simplified prognostic model JO - Eur Urol VL - 68 UR - https://doi.org/10.1016/j.eururo.2014.09.022 DO - 10.1016/j.eururo.2014.09.022 ID - Gravis2015 ER - TY - JOUR AU - Pond, G. R. AU - Sonpavde, G. AU - de Wit, R. AU - Eisenberger, M. A. AU - Tannock, I. F. AU - Armstrong, A. J. PY - 2014 DA - 2014// TI - The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer JO - Eur Urol VL - 65 UR - https://doi.org/10.1016/j.eururo.2013.09.024 DO - 10.1016/j.eururo.2013.09.024 ID - Pond2014 ER - TY - JOUR AU - Poulsen, M. H. AU - Rasmussen, J. AU - Edenbrandt, L. AU - Hoilund-Carlsen, P. F. AU - Gerke, O. AU - Johansen, A. AU - Lund, L. PY - 2016 DA - 2016// TI - Bone scan index predicts outcome in patients with metastatic hormone-sensitive prostate cancer JO - BJU Int VL - 117 UR - https://doi.org/10.1111/bju.13160 DO - 10.1111/bju.13160 ID - Poulsen2016 ER - TY - JOUR AU - Nozawa, M. AU - Hara, I. AU - Matsuyama, H. AU - Iki, M. AU - Nagao, K. AU - Nishioka, T. AU - Komura, T. AU - Esa, A. AU - Uejima, S. AU - Imanishi, M. PY - 2015 DA - 2015// TI - Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis JO - World J Urol VL - 33 UR - https://doi.org/10.1007/s00345-014-1431-1 DO - 10.1007/s00345-014-1431-1 ID - Nozawa2015 ER - TY - JOUR AU - Goodman, O. B. AU - Symanowski, J. T. AU - Loudyi, A. AU - Fink, L. M. AU - Ward, D. C. AU - Vogelzang, N. J. PY - 2011 DA - 2011// TI - Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer JO - Clin Genitourin Cancer VL - 9 UR - https://doi.org/10.1016/j.clgc.2011.04.001 DO - 10.1016/j.clgc.2011.04.001 ID - Goodman2011 ER - TY - JOUR AU - Tsuchiya, N. AU - Wang, L. AU - Suzuki, H. AU - Segawa, T. AU - Fukuda, H. AU - Narita, S. AU - Shimbo, M. AU - Kamoto, T. AU - Mitsumori, K. AU - Ichikawa, T. PY - 2006 DA - 2006// TI - Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.02.9439 DO - 10.1200/JCO.2005.02.9439 ID - Tsuchiya2006 ER -